
Biosimilars Insights
Evaluation of the risks, opportunities, and strategies underlying biosimilars development and defense.
Already a Subscriber?
Evaluation of the risks, opportunities, and strategies underlying biosimilars development and defense.
Obtain a full view of market and competitive positioning with reliable and up-to-date product analysis and worldwide net sales roll ups by molecule, therapy area, and company.
Utilize a multi-client subscription service to enable drug label and label claim comparisons across geographies and therapeutic areas.
One year ago, we welcomed Decision Resources Group (DRG) to the Clarivate portfolio of brands. Today we mark the next step in...
In DRG Blog / Mar, 2021
Digital pharmacies, which provide a faster and easier way to get prescriptions, are implementing new technologies to improve...
In DRG Blog / Feb, 2021
In the United States, as the COVID-19 pandemic shuttered non-essential businesses, millions lost their jobs and with them...
In DRG Blog / Feb, 2021
The approval of Shanghai Henlius Biotech’s HLX01—a biosimilar of rituximab (Roche’s MabThera)—in February 2019 marked...
In DRG Blog / Feb, 2021
From potential shortages of generic drugs to a brand new COVID-19 pipeline, this pandemic is undoubtedly impacting pharmacy...
In DRG Blog / Feb, 2021